Tomuzotuximab

N/A

Report date: 2025/09/29 20:01:14

Base Information

Drug NameTomuzotuximab

Drug Alias NameCetuximab biobetter (Glycotope)CetuGEXGT-MAB-5.2-GEX

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumPolandRomania +[8]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlycotope Gmbh

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGlycotope Gmbh

Active IndicationsN/A

Inactive IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck

ATC CodeL01XC06